These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26058080)

  • 1. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.
    Cole A; Wang Z; Coyaud E; Voisin V; Gronda M; Jitkova Y; Mattson R; Hurren R; Babovic S; Maclean N; Restall I; Wang X; Jeyaraju DV; Sukhai MA; Prabha S; Bashir S; Ramakrishnan A; Leung E; Qia YH; Zhang N; Combes KR; Ketela T; Lin F; Houry WA; Aman A; Al-Awar R; Zheng W; Wienholds E; Xu CJ; Dick J; Wang JC; Moffat J; Minden MD; Eaves CJ; Bader GD; Hao Z; Kornblau SM; Raught B; Schimmer AD
    Cancer Cell; 2015 Jun; 27(6):864-76. PubMed ID: 26058080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
    Larkin K; Byrd JC
    Cancer Cell; 2015 Jun; 27(6):747-9. PubMed ID: 26058072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.
    Zhang R; Wang P; Wei B; Chen L; Song X; Pan Y; Li J; Gan J; Zhang T; Yang CG
    Eur J Med Chem; 2023 Oct; 258():115577. PubMed ID: 37352796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
    Ishizawa J; Zarabi SF; Davis RE; Halgas O; Nii T; Jitkova Y; Zhao R; St-Germain J; Heese LE; Egan G; Ruvolo VR; Barghout SH; Nishida Y; Hurren R; Ma W; Gronda M; Link T; Wong K; Mabanglo M; Kojima K; Borthakur G; MacLean N; Ma MCJ; Leber AB; Minden MD; Houry W; Kantarjian H; Stogniew M; Raught B; Pai EF; Schimmer AD; Andreeff M
    Cancer Cell; 2019 May; 35(5):721-737.e9. PubMed ID: 31056398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
    Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
    Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLPP deficiency ameliorates neurodegeneration caused by impaired mitochondrial protein synthesis.
    Rumyantseva A; Popovic M; Trifunovic A
    Brain; 2022 Mar; 145(1):92-104. PubMed ID: 35240691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of the mitochondrial matrix peptidase ClpP in muscle cells causes mitochondrial dysfunction and decreases cell proliferation.
    Deepa SS; Bhaskaran S; Ranjit R; Qaisar R; Nair BC; Liu Y; Walsh ME; Fok WC; Van Remmen H
    Free Radic Biol Med; 2016 Feb; 91():281-92. PubMed ID: 26721594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma.
    Wang P; Zhang T; Wang X; Xiao H; Li H; Zhou LL; Yang T; Wei B; Zhu Z; Zhou L; Yang S; Lu X; Zhang Y; Huang Y; Gan J; Yang CG
    Cell Chem Biol; 2022 Sep; 29(9):1396-1408.e8. PubMed ID: 35905743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of small-molecule modulators for ClpP protease activity.
    Ye F; Li J; Yang CG
    Mol Biosyst; 2016 Dec; 13(1):23-31. PubMed ID: 27831584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial Caseinolytic Protease P: A Possible Novel Prognostic Marker and Therapeutic Target in Cancer.
    Cormio A; Sanguedolce F; Pesce V; Musicco C
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mitochondrial proteases in leukemic cells and leukemic stem cells.
    Mirali S; Schimmer AD
    Stem Cells Transl Med; 2020 Dec; 9(12):1481-1487. PubMed ID: 32761807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization.
    Hackl MW; Lakemeyer M; Dahmen M; Glaser M; Pahl A; Lorenz-Baath K; Menzel T; Sievers S; Böttcher T; Antes I; Waldmann H; Sieber SA
    J Am Chem Soc; 2015 Jul; 137(26):8475-83. PubMed ID: 26083639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of ClpP Protease in Bacterial Pathogenesis and Human Diseases.
    Bhandari V; Wong KS; Zhou JL; Mabanglo MF; Batey RA; Houry WA
    ACS Chem Biol; 2018 Jun; 13(6):1413-1425. PubMed ID: 29775273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
    Fennell EMJ; Aponte-Collazo LJ; Wynn JD; Drizyte-Miller K; Leung E; Greer YE; Graves PR; Iwanowicz AA; Ashamalla H; Holmuhamedov E; Lang H; Karanewsky DS; Der CJ; Houry WA; Lipkowitz S; Iwanowicz EJ; Graves LM
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00993. PubMed ID: 35929764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
    Zhang J; Luo B; Sui J; Qiu Z; Huang J; Yang T; Luo Y
    Biochem Pharmacol; 2022 Oct; 204():115232. PubMed ID: 36030831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target.
    Ollinger J; O'Malley T; Kesicki EA; Odingo J; Parish T
    J Bacteriol; 2012 Feb; 194(3):663-8. PubMed ID: 22123255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
    Zhou J; Chong PS; Lu X; Cheong LL; Bi C; Liu SC; Zhou Y; Tan TZ; Yang H; Chung TH; Zeng Q; Chng WJ
    Exp Hematol; 2014 Dec; 42(12):1041-52.e1-2. PubMed ID: 25139404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
    Greer YE; Hernandez L; Fennell EMJ; Kundu M; Voeller D; Chari R; Gilbert SF; Gilbert TSK; Ratnayake S; Tang B; Hafner M; Chen Q; Meerzaman D; Iwanowicz E; Annunziata CM; Graves LM; Lipkowitz S
    Cancer Res Commun; 2022 Oct; 2(10):1144-1161. PubMed ID: 36388465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.